Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines

MT Newswires Live10-09

Moderna (MRNA) and other vaccine developers were up on Friday after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate the development of cancer vaccines.

Moderna shares were up 5.4% around 10:50 am ET, while shares of Merck (MRK) and Novavax (NVAX) were up 1.7% and 9.2%, respectively. Shares of BioNTech (BNTX), Vaxcyte (PCVX) and Vir Biotechnology (VIR) were up 2.5%, 5.7% and 3.1%

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 207.71, Change: +10.71, Percent Change: +5.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment